Signaling Cascades Determining Cell Fate in a Glaucoma
About the Research Project
Program
Award Type
Standard
Award Amount
$35,000
Active Dates
July 01, 2002 - June 30, 2003
Grant ID
G2002011
Summary
The precise pathogenic mechanisms that lead to retinal ganglion cell (RGC) death in glaucoma is unknown. Despite the vulnerability of RGCs in glaucoma, glial cells located in the optic nerve head, or retina, survive glaucomatous stress. Dr. Tezel has hypothesized that this different susceptibility to damage is due to differential activity of signaling cascades in these cell types. To determine the validity of this hypothesis, he is conducting in vitro cell culture experiments with each cell type separately and in co-culture to examine the signaling cascades in response to elevated hydrostatic pressure. He will also determine the activation of specific kinases in an in vivo rat model of high-pressure glaucoma, and in human donor eyes affected by glaucoma. It is hoped that the information gained from these studies will help describe the mechanisms determining the fate of cells in response to glaucoma, and may provide targets for possible new drugs to treat the condition.
Related Grants
National Glaucoma Research
From Resilience to Vulnerability: How Stress Accelerates Aging
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Dorota Skowronska-Krawczyk, PhD
Current Organization
University Of California, Irvine
From Resilience to Vulnerability: How Stress Accelerates Aging
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Dorota Skowronska-Krawczyk, PhD
Current Organization
University Of California, Irvine
National Glaucoma Research
Novel Mechanisms to Regulate Eye Pressure
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Colleen McDowell, PhD
Current Organization
University of Wisconsin-Madison
Novel Mechanisms to Regulate Eye Pressure
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Colleen McDowell, PhD
Current Organization
University of Wisconsin-Madison
National Glaucoma Research
Developing a New Glaucoma Treatment That Avoids Daily Drops
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Gavin Roddy, MD, PhD
Current Organization
Mayo Clinic, Rochester
Developing a New Glaucoma Treatment That Avoids Daily Drops
Active Dates
July 01, 2025 - June 30, 2027
Principal Investigator
Gavin Roddy, MD, PhD
Current Organization
Mayo Clinic, Rochester